Is High-Grade Tumor Budding an Independent Prognostic Factor in Stage II Colon Cancer?

被引:2
|
作者
Kyong Shin, Jung [1 ]
Ah Park, Yoon [1 ]
Wook Huh, Jung [1 ]
Hyeon Yun, Seong [1 ]
Cheol Kim, Hee [1 ]
Yong Lee, Woo [1 ]
Hyung Kim, Seok [2 ]
Yun Ha, Sang [2 ]
Cho, Yong Beom [1 ,3 ,4 ,5 ]
机构
[1] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Surg, Seoul, South Korea
[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Pathol, Seoul, South Korea
[3] Sungkyunkwan Univ, Dept Hlth Sci & Technol, SAIHST, Seoul, South Korea
[4] Sungkyunkwan Univ, Dept Biopharmaceut Convergence, Seoul, South Korea
[5] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Surg, 81 Irwon Ro, Seoul 06351, South Korea
关键词
Adjuvant chemotherapy; High grade; Prognostic factor; Stage II colon cancer; Tumor budding; ADJUVANT SYSTEMIC CHEMOTHERAPY; COMPLETE RESECTION; COLORECTAL-CANCER; FLUOROURACIL; LEVAMISOLE; SURVIVAL; INDEX; RECOMMENDATIONS; EFFICACY; THERAPY;
D O I
10.1097/DCR.0000000000002345
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND: Risk factors, including lymphatic, vascular, and perineural invasion, are considered indications for adjuvant treatment in stage II colon cancer. However, tumor budding is not included in the above risk factors.OBJECTIVE: This study aimed to assess the value of tumor budding as a prognostic factor in stage II colon cancer. DESIGN: This is a retrospective cohort study.SETTINGS: This study was conducted in a tertiary referral center.PATIENTS: This study examined 1390 patients with stage II colon cancer who received curative resection from 2007 to 2013 at an institution.INTERVENTIONS: These patients were classified according to tumor budding status: low-grade tumor budding (less than 10 buds) and high-grade tumor budding (10 buds or more). Differences between the 2 groups were corrected by propensity score matching.MAIN OUTCOME MEASURES: Disease-free survival and overall survival were the primary end points.RESULTS: Among 1390 patients, 146 (10.5%) had highgrade tumor budding. The high-grade tumor budding group showed adverse histological characteristics such as advanced T stage, histological grade of differentiation, and presence of lymphatic/perineural invasion. After matching, the 5-year disease-free survival rate for the high-grade tumor budding group was significantly lower than for the low-grade group. We also compared survival outcomes according to tumor budding grade for patients who did not have risk factors and did not receive adjuvant treatment. The 5-year overall survival was similar between the 2 groups. However, the 5-year disease-free survival decreased significantly in the high-grade tumor budding group than in the low-grade tumor budding group. LIMITATIONS: This was a retrospective study with a single-center design.CONCLUSIONS: High-grade tumor budding is a poor prognostic factor in stage II colon cancer and is considered one of the risk factors for adjuvant treatment. See Video Abstract at http://links.lww.com/DCR/B962.
引用
收藏
页码:E801 / E808
页数:8
相关论文
共 50 条
  • [41] Tumor Budding Is an Independent Adverse Prognostic Factor in Pancreatic Ductal Adenocarcinoma
    O'Connor, K. M.
    Li-Chang, H. H.
    Kalloger, S. E.
    Webber, D. L.
    Owen, D. A.
    Schaeffer, D. F.
    [J]. MODERN PATHOLOGY, 2014, 27 : 452A - 452A
  • [42] Tumor Budding Is an Independent Adverse Prognostic Factor in Pancreatic Ductal Adenocarcinoma
    O'Connor, K. M.
    Li-Chang, H. H.
    Kalloger, S. E.
    Webber, D. L.
    Owen, D. A.
    Schaeffer, D. F.
    [J]. LABORATORY INVESTIGATION, 2014, 94 : 452A - 452A
  • [43] Tumor Budding Is an Independent Adverse Prognostic Factor in Pancreatic Ductal Adenocarcinoma
    O'Connor, Kate
    Li-Chang, Hector H.
    Kalloger, Steven E.
    Peixoto, Renata D.
    Webber, Douglas L.
    Owen, David A.
    Driman, David K.
    Kirsch, Richard
    Serra, Stefano
    Scudamore, Charles H.
    Renouf, Daniel J.
    Schaeffer, David F.
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (04) : 472 - 478
  • [44] TUMOR SIZE AS A PROGNOSTIC FACTOR IN PATIENTS WITH EARLY-STAGE COLON CANCER
    Rizzo, G.
    Santullo, F.
    Biondi, A.
    D'Ugo, D.
    Mattana, C.
    Coco, C.
    Persiani, R.
    [J]. DISEASES OF THE COLON & RECTUM, 2015, 58 (05) : E318 - E319
  • [45] Prognostic significance of primary tumor localization in stage II and III colon cancer
    Sakin, Abdullah
    Arici, Serdar
    Secmeler, Saban
    Can, Orcun
    Geredeli, Caglayan
    Yasar, Nurgul
    Demir, Cumhur
    Demir, Osman Gokhan
    Cihan, Sener
    [J]. WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2018, 10 (11) : 410 - 420
  • [46] Prognostic Impact of Tumor-Budding Grade in Stages 1–3 Colon Cancer: A Retrospective Cohort Study
    Bo Young Oh
    Yoon Ah Park
    Jung Wook Huh
    Seong Hyeon Yun
    Hee Cheol Kim
    Ho-Kyung Chun
    Seok Hyung Kim
    Sang Yun Ha
    Woo Yong Lee
    Yong Beom Cho
    [J]. Annals of Surgical Oncology, 2018, 25 : 204 - 211
  • [47] Prognostic effect of tumor location in stage II and III colon cancer.
    Ozveren, Ahmet
    Surmeli, Zeki Gokhan
    Turgut, Asli
    Karaca, Burcak
    Karabulut, Bulent
    Sanli, Ulus Ali
    Uslu, Ruchan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients
    Farina-Sarasqueta, A.
    van Lijnschoten, G.
    Moerland, E.
    Creemers, G. -J.
    Lemmens, V. E. P. P.
    Rutten, H. J. T.
    van den Brule, A. J. C.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 (12) : 2396 - 2402
  • [49] Independent Validation of a Prognostic Genomic Signature (ColoPrint) for Patients With Stage II Colon Cancer
    Maak, Matthias
    Simon, Iris
    Nitsche, Ulrich
    Roepman, Paul
    Snel, Mireille
    Glas, Annuska M.
    Schuster, Tibor
    Keller, Gisela
    Zeestraten, Eliane
    Goossens, Ines
    Janssen, Klaus-Peter
    Friess, Helmut
    Rosenberg, Robert
    [J]. ANNALS OF SURGERY, 2013, 257 (06) : 1053 - 1058
  • [50] Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer patients
    Rosenberg, R.
    Maak, M.
    Simon, I.
    Nitsche, U.
    Schuster, T.
    Kuenzli, B.
    Keerl, A.
    Friess, H.
    Kocher, T.
    [J]. BRITISH JOURNAL OF SURGERY, 2012, 99 : 9 - 9